StimCell Energetics Inc. Announces Study into eBalance(R) Device's Impact on Neuronal Mitochondrial Function

Rhea-AI Summary

StimCell Energetics (OTCQB: STME) announced a service agreement, effective December 1, 2025, with St. Boniface Hospital Albrechtsen Research Centre and Principal Investigator Professor Paul Fernyhough to study the eBalance® device.

The approximately three-month project will test how eBalance® microcurrent stimulation affects mitochondrial function in cultured sensory neurons. Experiments will measure oxygen consumption rates (OCR) and related metrics—ATP production, glycolysis, basal and maximal respiration, spare respiratory capacity, coupling efficiency, and proton leak—plus AMPK activity and respiratory protein levels via Western blot. The study uses acute and longer-term stimulation of dissociated adult rat dorsal root ganglia neurons and will deliver a comprehensive report at conclusion.

News Market Reaction – STME

-9.83%

1 alert

-9.83% News Effect

On the day this news was published, STME declined 9.83%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Net loss: $265,602 Prior-year net loss: $66,919 Cash balance: $6,437 +5 more

8 metrics

Net loss $265,602 Q1 FY2026 (three months ended August 31, 2025)

Prior-year net loss $66,919 Same quarter prior year

Cash balance $6,437 End of Q1 FY2026

Working capital deficit $1,393,949 End of Q1 FY2026

Total liabilities $1,410,336 End of Q1 FY2026

Cash used in operations $108,142 Q1 FY2026

Financing cash inflow $100,000 Related-party credit line at 10% per annum (Q1 FY2026)

Common shares outstanding 20,641,272 As of October 14, 2025

Market Reality Check

Price: $0.3001 Vol: Volume 2,929 is about 1.1...

normal vol

$0.3001 Last Close

Volume Volume 2,929 is about 1.16x the 20-day average of 2,533 shares. normal

Technical Price 0.3594 is trading above the 200-day MA at 0.33, after a 3.09% gain.

Peers on Argus

Peers showed mixed moves: RMSL down 9.09%, BIEL up 17.65%, while ADMT, ODYY, and...

Peers showed mixed moves: RMSL down 9.09%, BIEL up 17.65%, while ADMT, ODYY, and NGMDF were flat. STME’s 3.09% gain appears stock-specific rather than a broad medical devices move.

Market Pulse Summary

The stock moved -9.8% in the session following this news. A negative reaction despite the collaborat...

Analysis

The stock moved -9.8% in the session following this news. A negative reaction despite the collaborative research news would fit a context where balance sheet risk dominated. The company recently reported a net loss of $265,602, cash of $6,437, and a working capital deficit of $1,393,949, together with substantial doubt about going concern. Under such conditions, investors have often focused more on funding gaps and dilution risk than on early-stage exploratory studies.

Key Terms

mitochondrial function, oxygen consumption rates (OCR), electron transport chain, glycolysis, +4 more

8 terms

mitochondrial function medical

"explore the effects of StimCell's proprietary eBalance® device on mitochondrial function"

Mitochondrial function describes how well mitochondria — the cell’s tiny power plants — produce energy and keep cells healthy. Investors watch it because many drugs, diagnostics and safety tests target or rely on healthy mitochondria; changes in mitochondrial function can signal a treatment’s effectiveness, side effects, or a new market opportunity in diseases tied to energy failure. Think of it as a company’s engine performance indicator for biological systems.

oxygen consumption rates (OCR) medical

"the study will measure oxygen consumption rates (OCR) to evaluate impacts on the electron"

Oxygen consumption rates measure how much oxygen cells, tissues or biological systems use over time; think of it as the “fuel burn” of living material. Investors care because these rates reveal how a drug, treatment or manufacturing process affects cell metabolism, safety and effectiveness—key signals about a therapy’s mechanism, potential side effects, or production quality. Changes in oxygen use can influence clinical success, regulatory review and commercial prospects.

electron transport chain medical

"OCR to evaluate impacts on the electron transport chain, ATP production, glycolysis"

A series of protein complexes in cell mitochondria that pass along electrons to produce the cell’s main energy molecule, acting like a factory assembly line that turns raw fuel into usable power. Investors should care because many drugs, diagnostics and safety concerns target or affect this energy process—changes can signal disease mechanisms, drug effects, or toxic side effects that influence a biotech or pharmaceutical company's prospects.

glycolysis medical

"electron transport chain, ATP production, glycolysis, basal respiration, maximal respiration"

Glycolysis is the basic chemical pathway cells use to break down sugar into smaller parts and release usable energy, like a small power plant converting fuel into electricity. For investors, glycolysis matters because many drugs, diagnostics and regulatory decisions target or measure this pathway in conditions such as metabolic diseases and cancer; changes in glycolysis can indicate how a therapy works or whether a company’s product addresses a key biological need.

AMP-activated protein kinase (AMPK) medical

"analyses will quantify enzyme activities such as AMP-activated protein kinase (AMPK)"

Adenosine monophosphate–activated protein kinase (AMPK) is a cellular “energy sensor” enzyme that detects low energy and switches on processes that generate fuel while turning off energy-consuming tasks, much like a thermostat that adjusts heating when a room gets cold. It matters to investors because drugs or therapies that target AMPK can change how the body handles diabetes, obesity, heart disease and some cancers, affecting clinical trial prospects, regulatory approval paths and market value for companies developing such treatments.

Western blotting medical

"and levels of respiratory proteins through Western blotting."

A laboratory method that identifies and measures specific proteins in a biological sample by separating them and then using a labeled probe to reveal the target, similar to finding a particular needle in a pile of needles by size and then tagging it with a bright sticker. For investors, western blotting matters because it provides evidence that a drug, vaccine, diagnostic test, or manufacturing process is producing the intended protein, which helps validate scientific claims, support regulatory filings, and reduce technical risk.

dorsal root ganglia (DRG) neurons medical

"stimulation of dissociated adult rat dorsal root ganglia (DRG) neurons under controlled"

Clusters of nerve cells located just outside the spinal cord that act like relay stations, carrying sensory signals—such as touch, temperature and pain—from the body into the central nervous system. They matter to investors because many drug, device and gene therapy programs for chronic pain, neuropathy and sensory disorders target these cells; success or failure of such therapies can drive clinical, regulatory and commercial outcomes for healthcare companies.

bioenergetics medical

"a renowned expert in neuronal bioenergetics and peripheral neuropathy, brings decades"

Bioenergetics is the study of how living cells generate, store and use energy—think of cells as tiny engines or batteries that power all biological functions. For investors, it matters because therapies, diagnostics or products that change how cells manage energy can create new markets or disrupt existing ones, affecting a company’s revenue potential, development costs and regulatory risks in sectors like biotech, pharmaceuticals and agriculture.

AI-generated analysis. Not financial advice.

VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, today announced the signing of a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, affiliated with the University of Manitoba, and Principal Investigator, Professor Paul Fernyhough. This collaboration will explore the effects of StimCell's proprietary eBalance® device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents.

Under the agreement, effective December 1, 2025, Dr. Fernyhough's team will conduct a series of experiments to assess how eBalance® stimulation influences key aspects of cellular energy production by mitochondria. Using established biological assays in Dr. Fernyhough's laboratory, the study will measure oxygen consumption rates (OCR) to evaluate impacts on the electron transport chain, ATP production, glycolysis, basal respiration, maximal respiration, spare respiratory capacity, coupling efficiency, and proton leak. Additional analyses will quantify enzyme activities such as AMP-activated protein kinase (AMPK) and levels of respiratory proteins through Western blotting. The project, expected to span approximately three months, involves acute and longer-term stimulation of dissociated adult rat dorsal root ganglia (DRG) neurons under controlled conditions. Replicates will ensure robust statistical analysis, with a comprehensive report provided at the study's conclusion.

"We are thrilled to partner with Dr. Fernyhough and the esteemed St Boniface Hospital Albrechtsen Research Centre to rigorously test eBalance®'s capabilities," said David Jeffs, CEO of StimCell Energetics. "This research represents a significant step forward in understanding how our technology may enhance mitochondrial performance, potentially opening new avenues for therapeutic applications in neurology and beyond."

Dr. Paul Fernyhough, www.sbrc.ca/fernyhough, a renowned expert in neuronal bioenergetics and peripheral neuropathy, brings decades of experience to the project. His prior work, including studies on bioenergetic parameters in diabetic models, aligns closely with StimCell's mission to advance cellular energy solutions. This agreement underscores the Company's commitment to evidence-based innovation.

About StimCell Energetics Inc.

StimCell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance® Technology and its eBalance® Home System.

On behalf of the Board of Directors of StimCell Energetics Inc.

David Jeffs
CEO, Director

For further information:

info@stimcell.com
www.StimCell.com

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. Except as required by law, StimCell Energetics Inc. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that StimCell Energetics Inc. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

SOURCE: StimCell Energetics

View the original press release on ACCESS Newswire

FAQ

What did StimCell Energetics (STME) announce on December 2, 2025 about the eBalance® study?

StimCell announced a service agreement effective December 1, 2025 with St. Boniface Hospital Albrechtsen Research Centre to study eBalance® effects on neuronal mitochondrial function.

Who is the principal investigator for the STME eBalance® mitochondrial study and where is the lab located?

The principal investigator is Professor Paul Fernyhough at St. Boniface Hospital Albrechtsen Research Centre, affiliated with the University of Manitoba.

What assays will the STME-funded study measure to assess mitochondrial function?

The study will measure OCR, ATP production, glycolysis, basal/maximal respiration, spare respiratory capacity, coupling efficiency, proton leak, AMPK activity, and respiratory protein levels via Western blot.

How long will the StimCell eBalance® neuronal study (STME) run?

The project is expected to span approximately three months and includes acute and longer-term stimulation experiments.

What cell model will be used in StimCell's eBalance® study announced by STME?

Researchers will use dissociated adult rat dorsal root ganglia (DRG) sensory neurons under controlled conditions.

Will StimCell (STME) publish results from the eBalance® mitochondrial experiments?

The agreement specifies that a comprehensive report will be provided at the study's conclusion.